Advancing Structural Characterization of Therapeutic Proteins Microfluidic Modulation Spectroscopy with AMGEN Webinar

In this webinar you will discover how data quality can be significantly improved through the use of Microfluidic Modulation Spectroscopy (MMS); a novel automated IR technology that has proven to be an effective technique for generating high-quality, reproducible secondary structure data for protein therapeutics including monoclonal antibodies, even at low concentrations. Data will be shared to illustrate how researchers at Amgen Inc. of Thousand Oaks, CA analyzed monoclonal antibodies(mAbs) at concentrations ranging from 0.5 to 50 mg/mL and obtained superior data by optimizing detector dwell time settings. Additionally, we will discuss how the ability to generate reproducible data with high sensitivity at low formulation concentrations supports the use of MMS as a more reliable, cost-effective, and comprehensive method for evaluating the secondary structure of low concentration biotherapeutic formulations and modalities vs traditional IR techniques.